Share Twitter LinkedIn Facebook Email Earn CME Credit: https://naccme.com/program/7306 In this presentation from the 23rd Annual Perspectives in Thoracic Oncology, Dr. Charu Aggarwal discusses frontline options for targeted therapy with EGFR TKIs. © 2018 Imedex, an HMP Company
FDA Grants Priority Review Zongertinib for HER2-Mutant NSCLC | Breakthrough in Lung Cancer Treatment Non-Small Cell Lung Cancer 5 Mins Read
Plasma ctDNA Kinetics as a Predictor of Systemic Therapy Response in Advanced NSCLC Non-Small Cell Lung Cancer 3 Mins Read
VIDEO: iTeos and GSK’s TIGIT Combination Therapy Shows Significant Promise at ESMO 2024 Non-Small Cell Lung Cancer 2 Mins Read